Eli Lilly signals interest in researching and improving psychedelic ibogaine, says neuroscience chief
read at Endpoints ↗Positive
At a recent psychedelics conference, Eli Lilly’s neuroscience president Carole Ho announced the company’s interest in studying ibogaine.
Ho said Lilly aims to improve the drug’s safety and efficacy profile through research and development efforts.
The comment reflects Lilly’s broader exploration of psychedelic therapeutics, though no specific programs or timelines were disclosed.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly interested in ibogaine investments, its neuro leader says”
read at Endpoints ↗114 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that